Then Le (Nirapali) first-line adaptive disease was approved! The only PARP inhibitor approved for first-line maintenance therapy in all populations of ovarian cancer.

On September 10, 2020, Redding Pharmaceuticals (NASDAQ: ZLAB) announced today that the State Drug Administration has approved the listing of a new supplemental drug for Cyril ® (Nirapali) for maintenance therapy after complete or partial remission of first-line platinum-containing chemotherapy in adult patients with advanced epithelitis, fallopian tube cancer, or primary peritoneal cancer.
is an oral PARP inhibitor once a day. Dr. Ying Du, founder, chairman and chief executive officer of
Redding Pharmaceuticals, said, "Nirapali is the only one approved in China and around the world, and can be used as a single parp inhibitor for first-line and relapsed ovarian cancer maintenance treatment, regardless of the patient's biomarker status.
believe that Nirapali has the potential to be the best PARP inhibitor of its kind.
rapid approval of this new adaptation is further evidence that there are still significant unsolvict clinical needs for first-line maintenance treatment of ovarian cancer.
Thanks to the guidance and support given by the State Drug Administration, the Drug Review Center and the Shanghai Municipal Drug Administration in the review and review process of Nirapali's first-line adaptive disorders, we will continue our efforts to bring innovative medicines and therapies to more Chinese patients as quickly as possible.
Professor Wu Lingying, Director of Gynaecology at the Oncology Hospital of the Chinese Academy of Medical Sciences, said: "The approval of nirapa's new adaptation to first-line maintenance therapy is expected to change the way ovarian cancer is treated in China.
Nirapali's studies as a single-drug maintenance treatment have shown positive clinical efficacy in the ovarian cancer patient population, as well as its superior pharmacogenetic properties as a once-a-day treatment, including the ability to penetrate the blood-brain barrier.
" National Drug Administration accepted an application for a new supplement for Nirapali's first-line maintenance therapy in March 2020 and granted it priority review eligibility in April.
.